Mood Disorders in Head and Neck Cancer Patients

• Status: Not yet recruiting
• Trial end date: 2026-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to initiate a pharmacotherapy protocol for at-risk patients with newly diagnosed head and neck cancer in order to decrease the incidence of anxiety, depression, and uncontrolled pain during cancer treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Alabama at Birmingham
• Treatments: Venlafaxine Hydrochloride

Criteria

Inclusion Criteria:

1. Provision of signed and dated informed consent form

2. Stated willingness to comply with all study procedures and availability for the duration of the study

3. Male or female, aged 18 years or older

4. Ability to speak and understand English

5. Have a recently diagnosed cutaneous or mucosal malignancy

6. Scheduled to undergo treatment for their malignancy (surgical or nonsurgical) with curative intent

7. Ability to take medication (by mouth or via parenteral route)

8. Willing to adhere to the study drug's dosing protocol

Exclusion Criteria:

1. Age less than 18 years

2. Inability to speak or understand English

3. Primary malignancy of thyroid or parathyroid origin

4. Currently meet diagnostic criteria for psychosis, schizophrenia, or moderate/severe major depressive disorder (MDD)

5. Currently receiving medication as treatment for depression or anxiety

6. Known allergic reaction to components of study drug

7. Have uncontrolled pain or chronic pain disorder

8. Treatment with another investigational drug or other intervention within 30 days

9. Females of child-bearing age who are pregnant or nursing